NCT03202940 - A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 14, 2017

Primary Completion Date

January 1, 2029

Study Completion Date

January 1, 2031

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Alectinib

Alectinib is an oral ALK inhibitor. The term ALK inhibitor means that alectinib targets the abnormal ALK protein that is causing lung cancer cells to grow

DRUG

Cobimetinib

Cobimetinib is an oral inhibitor of MEK, a signaling protein that can cause some types of lung cancer to grow

Trial Locations (1)

02114

Massachusetts general Hospital, Boston